For Healthcare Professionals

Disease Overview of aHUS

atypical hemolytic uremic syndrome (aHUS) is a catastrophic disease that can result in sudden and progressive vital organ failure and premature death1-3

Significant morbidity and mortality within 1 year3

Study description: An analysis of the outcomes in 40 patients from the database of the International Registry of Recurrent and Familial HUS/TTP with the complement factor H (CFH) mutation. The cumulative fraction of patients free of events (defined as the combination of the occurrence of chronic renal insufficiency or initiation of dialysis or death, whichever occurred first after the onset of HUS) was estimated by Kaplan-Meier analysis.3

  • 94% of CFH patients in this trial received plasma exchange or plasma infusion (PE/PI) for the first thrombotic microangiopathy (TMA) manifestation3

Across all aHUS patients, SUDDEN AND PROGRESSIVE MORBIDITY and MORTALITY occur regardless of mutational status3,4

1. Sallée M, Daniel L, Piercecchi MD, et al. Nephrol Dial Transplant. 2010;25:2028-2032. 2. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Semin Thromb Hemost. 2010;36:673-681. 3. Caprioli J, Noris M, Brioschi S, et al; International Registry of Recurrent and Familial HUS/TTP. Blood. 2006;108:1267-1279. 4. Noris M, Caprioli J, Bresin E, et al. Clin J Am Soc Nephrol. 2010;5:1844-1859.